罗沙司他对维持性血液透析肾性贫血患者的疗效

Efficacy of rosalta in the treatment of maintenance hemodialysis patients with renal anemia

目的研究罗沙司他治疗维持性血液透析(MHD)肾性贫血患者的效果及其对炎症反应水平及铁代谢的影响。方法将107例MHD肾性贫血患者采用随机数字表法分为观察组和对照组,对照组53例给予琥珀亚酸铁联合重组人促红素治疗,观察组54例给予琥珀亚酸铁联合罗沙司他进行治疗,对比两组患者贫血指标、铁代谢水平、炎症反应水平和不良反应。结果观察组治疗后血红蛋白、红细胞计数、血细胞比容水平均高于对照组(P<0.05);观察组治疗后转铁蛋白饱和度、血清铁蛋白、转铁蛋白水平均高于对照组(P<0.05);观察组治疗后白细胞介素-6、C反应蛋白、肿瘤坏死因子-α水平均低于对照组(P<0.05);两组不良反应发生率比较,P<0.05。结论罗沙司他联合琥珀亚酸铁治疗MHD肾性贫血效果确切,能够有效改善铁代谢水平,纠正贫血状态,降低炎症反应水平,安全性较高。

Objective To investigate the efficacy of rosalta in the treatment of maintenance hemodialysis(MHD)patients with renal anemia.Methods A total of 107 MHD patients with renal anemia in our hospital were randomly divided into two groups.53 patients in the control group were treated with ferrous succinate and recombinant human erythrotropin(rhEPO)and 54 patients in the observation group were treated with ferrous succinate and rosalta.Anemia index,iron metabolism level,inflammatory response level and adverse reactions were compared between the two groups.Results After treatment,the levels of hemoglobin(Hb),red blood cell count(RBC)and hematocrit(Hct)in the observation group were higher than those in control group(P<0.05).After treatment,the transferrin saturation(TSAT),serum ferritin(SF)and transferrin(TRF)levels in observation group were higher than those in control group(P<0.05);the levels of interleukin-6(IL-6),C-reactive protein(CRP)and tumor necrosis factor-α(TNF-α)in observation group were lower than those in control group(P<0.05).Theere was significant difference in the incidence of adverse reaction between the two groups(P<0.05).Conclusion Rosalta combined with ferrous succinate has definite effect in the treatment of MHD patients with renal anemia,which can effectively improve the level of iron metabolism,correct the state of anemia,and reduce the level of inflammatory response with high safety.